Abvc biopharma announces vitargus phase ii clinical study investigator meeting

Fremont, ca, april 26, 2022 (globe newswire) -- via newmediawire  – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that the principal investigators of the phase ii clinical study of vitargus® will hold a virtual meeting on april 27, 2022. the meeting will be attended by all principal investigators currently selected from the australian and thailand sites to help coordinate the study, entitled “a prospective multi-site open label randomized controlled clinical investigation of the safety and effectiveness of abv-1701 ocular endotamponade (oe).”
ABVC Ratings Summary
ABVC Quant Ranking